This educational guide forms part of the additional risk minimisation measures for lisocabtagene maraleucel. It contains information regarding selected lisocabtagene maraleucel-associated adverse reactions of cytokine release syndrome (CRS), neurologic toxicities, including immune effector cell associated neurotoxicity syndrome (ICANS), and secondary malignancy of T-cell origin. These are not all the adverse reactions associated with lisocabtagene maraleucel. Please refer to the lisocabtagene maraleucel SmPC for more information.